Details
Stereochemistry | ACHIRAL |
Molecular Formula | CH2Cl2O6P2.2Na.4H2O |
Molecular Weight | 360.917 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.[Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O
InChI
InChIKey=XWHPUCFOTRBMGS-UHFFFAOYSA-L
InChI=1S/CH4Cl2O6P2.2Na.4H2O/c2-1(3,10(4,5)6)11(7,8)9;;;;;;/h(H2,4,5,6)(H2,7,8,9);;;4*1H2/q;2*+1;;;;/p-2
DescriptionSources: https://www.medicines.org.uk/emc/medicine/311 |
Sources: https://www.medicines.org.uk/emc/medicine/311 |
Clodronate (also known as clodronic acid) is a drug used to treat a high level of calcium in the blood caused by changes in the body that happen with cancer. Clodronate is approved in some countries and is sold under trade trade name bonefos for oral use. Bonefos is indicated in the management of osteolytic lesions, hypercalcemia and bone pain associated with skeletal metastases in patients with carcinoma of the breast or multiple myeloma. Bonefos is also indicated for the maintenance of clinically acceptable serum calcium levels in patients with hypercalcemia of malignancy initially treated with an intravenous bisphosphonate. Bonefos forms complexes with divalent metal ions, and therefore simultaneous administration with food, antacids and mineral supplements may impair absorption. It was suggested, that the mechanism of action of clodronate was involved osteoclast apoptosis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P05141 Gene ID: 292.0 Gene Symbol: SLC25A5 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11961144 |
|||
Target ID: P12236 Gene ID: 293.0 Gene Symbol: SLC25A6 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11961144 |
|||
Target ID: P12235 Gene ID: 291.0 Gene Symbol: SLC25A4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11961144 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Bonefos Approved UseBonefos tablets are indicated in the management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with carcinoma of the breast or multiple myeloma. Bonefos tablets are also indicated for the maintenance of clinically acceptable serum calcium levels in patients with hypercalcaemia of malignancy initially treated with an intravenous bisphosphonate. |
|||
Primary | Bonefos Approved UseBonefos tablets are indicated in the management of osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with carcinoma of the breast or multiple myeloma. Bonefos tablets are also indicated for the maintenance of clinically acceptable serum calcium levels in patients with hypercalcaemia of malignancy initially treated with an intravenous bisphosphonate. |
PubMed
Title | Date | PubMed |
---|---|---|
Strategies for management of prostate cancer-related bone pain. | 2001 |
|
Bisphosphonates in multiple myeloma. | 2001 |
|
[Bisphosphonates in the treatment of breast carcinoma]. | 2001 Aug |
|
Adjuvant bisphosphonate therapy: the future. | 2001 Aug |
|
Dosing regimens and main adverse events of bisphosphonates. | 2001 Aug |
|
Clinical and biochemical response to single infusion of clodronate in active rheumatoid arthritis--a double blind placebo controlled study. | 2001 Dec |
|
Effects of long-term administration of clodronate on growing rat bone. | 2001 Dec |
|
Novel therapeutic approaches to cancer patients with bone metastasis. | 2001 Dec |
|
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. | 2001 Dec |
|
Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. | 2001 Dec |
|
The cellular uptake and metabolism of clodronate in RAW 264 macrophages. | 2001 Nov |
|
Suppression of T cells results in long-term survival of mouse heart xenografts in C6-deficient rats. | 2001 Nov |
|
Bisphosphonates in the treatment of metastatic breast cancer. | 2001 Oct |
|
Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. | 2001 Oct |
|
Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. | 2001 Oct |
|
Critical role of Kupffer cell-derived IL-10 for host defense in septic peritonitis. | 2001 Oct 1 |
|
Meningeal and perivascular macrophages of the central nervous system play a protective role during bacterial meningitis. | 2001 Oct 15 |
|
The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. | 2001 Sep |
|
Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. | 2001 Sep |
|
Recent advances in breast cancer (the Twenty-fourth San Antonio Breast Cancer Symposium, December, 2001). | 2002 |
|
Treatment of complex regional pain syndrome type I. | 2002 |
|
Actions of bisphosphonates in animal models of breast cancer. | 2002 |
|
Development of bisphosphonates. | 2002 |
|
The present and future role of bisphosphonates in the management of patients with breast cancer. | 2002 |
|
Bisphosphonates for breast cancer. | 2002 |
|
Is there a dose response relationship for clodronate in the treatment of tumour induced hypercalcaemia? | 2002 Apr 22 |
|
Bisphosphonate space measurement and dosage requirement for intravenous clodronate treatment of Paget's disease. | 2002 Feb |
|
Clodronate in myelofibrosis: a case report. | 2002 Feb |
|
Electrospray ionization mass spectrometry and tandem mass spectrometry of clodronate and related bisphosphonate and phosphonate compounds. | 2002 Feb |
|
Rapid recovery of platelet count following administration of liposome-encapsulated clodronate in a mouse model of immune thrombocytopenia. | 2002 Feb |
|
Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. | 2002 Feb 1 |
|
Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats. | 2002 Jan |
|
Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. | 2002 Jan |
|
The role of perivascular and meningeal macrophages in experimental allergic encephalomyelitis. | 2002 Jan |
|
Does postmenopausal hormone replacement therapy affect cardiac autonomic regulation in osteoporotic women? | 2002 Jan-Feb |
|
The difluoromethylenesulfonic acid group as a monoanionic phosphate surrogate for obtaining PTP1B inhibitors. | 2002 Jul |
|
Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. | 2002 Jun |
|
Bisphosphonate prodrugs. | 2002 Jun |
|
Role of resident alveolar macrophages in leukocyte traffic into the alveolar air space of intact mice. | 2002 Jun |
|
Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. | 2002 Mar |
|
Disodium chlodronate prevents bone resorption in experimental periodontitis in rats. | 2002 Mar |
|
Reductions in bone mass, structure, and strength in axial and appendicular skeletons associated with increased turnover after ovariectomy in mature cynomolgus monkeys and preventive effects of clodronate. | 2002 Mar |
|
[Bisphosphonate therapy in Paget disease?]. | 2002 Mar 22 |
|
Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate. | 2002 May |
|
Effects of topical administration of clodronate on alveolar bone resorption in rats with experimental periodontitis. | 2002 May |
|
Macrophages are necessary for maximal nuclear factor-kappa B activation in response to endotoxin. | 2002 May |
|
Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. | 2002 May |
|
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. | 2002 May 1 |
|
Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. | 2002 May 20 |
|
The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. | 2002 May 6 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/medicine/311
A daily dose of 1600 mg should be taken as a single dose. When higher daily doses are used, the part of the dose exceeding 1600 mg should be taken separately (as a second dose) as recommended below.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16364054
Curator's Comment: It was found that due to high bisphosphonate-bone binding affinity, bone surface exposure to clodronate for 3 min. had maximal resorption inhibition. The mechanism of action of both clodronate and zoledronic acid involved osteoclast apoptosis, whereas pamidronate had only minor apoptotic effect at dosages, which readily inhibited resorption. Zoledronic acid was not metabolised into an intracellular ATP-analogue in vitro in contrast to clodronate
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
72292
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
||
|
NCI_THESAURUS |
C2136
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
||
|
NCI_THESAURUS |
C443
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
||
|
NCI_THESAURUS |
C67439
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
||
|
FDA ORPHAN DRUG |
40689
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
59586
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
88416-50-6
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
m3635
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL12318
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
NN-19
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
23724874
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
59587
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
DTXSID40237035
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
SUB130300
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
100000156397
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
N030400H8J
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
1546871
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | RxNorm | ||
|
N030400H8J
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
SUB13394MIG
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
C1418
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY | |||
|
DBSALT000972
Created by
admin on Fri Dec 15 15:12:52 GMT 2023 , Edited by admin on Fri Dec 15 15:12:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD